Allegro Diagnostics announces results from BronchoGen genomic test trial on lung cancer

Allegro Diagnostics today announced that results from its AEGIS (Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer) clinical trials, to determine the accuracy of the BronchoGen™ genomic test, have been accepted for an oral presentation during the late-breaking abstract session at CHEST 2012 on Tuesday, October 23, 2012 at 4:30 p.m. The abstract will also be published in a supplement of the October 2012 issue of CHEST. BronchoGen is Allegro Diagnostics' lead genomic test, and it is built upon the Company's molecular testing platform that utilizes gene expression of normal epithelial cells in the respiratory tract to detect signs of lung cancer. CHEST 2012 is the 78th annual meeting of the American College of Chest Physicians and is being held at the Georgia World Congress Center in Atlanta, October 20-25, 2012.    

"The goal for our first clinical trial analysis is to show significantly higher negative predictive value in lung cancer diagnoses using BronchoGen," said Duncan Whitney, Senior Vice President, Research, Development and Technical Operations of Allegro Diagnostics and the study's director. "We are eager to present our data that was obtained using RT-PCR at CHEST in October. We plan to use the PCR platform for routine clinical testing in the next year."

"BronchoGen may enable physicians to better diagnose patients suspected of having lung cancer, avoiding more costly and invasive procedures to confirm the disease," said Michael D. Webb, President and Chief Executive Officer of Allegro Diagnostics. "To date, Allegro has met all milestones as part of our development strategy for the BronchoGen genomic test, and we are currently preparing for its commercialization."